Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

mAbVista

mAbVista
2011 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
1 INVESTORS
Description

Operator of a biotechnology firm designed to specialize in the production of high quality monoclonal antibodies. The company provides highly specific, sensitive and versatile microscopy-qualified monoclonal antibodies for the acceleration and advancement of proteomics, enabling researchers to perform quantitative single cell analysis and high content drug screening.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • Two Greenway Plaza
  • Suite 910
  • Houston, TX 77046
  • United States

+1 (713) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore mAbVista’s full profile, request a free trial.

mAbVista Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

mAbVista Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BCM Technologies Venture Capital Minority 000 0000 000000 0

mAbVista Executive Team (3)

Name Title Board
Seat
Contact
Info
Dean Edwards Ph.D Co-Founder & Board Member
Michael Mancini Ph.D Co-Founder & Board Member
Shane Climie Ph.D President & Board Member

mAbVista Board Members (5)

Name Representing Role Since Contact
Info
Caroline Popper MD BCM Technologies Board Member 000 0000
Dean Edwards Ph.D mAbVista Co-Founder & Board Member 000 0000
Michael Dilling Ph.D Self Board Member 000 0000
Michael Mancini Ph.D mAbVista Co-Founder & Board Member 000 0000
Shane Climie Ph.D Self President & Board Member 000 0000